The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Oncogenic KRAS modulates mitochondrial metabolism in human colon cancer cells by inducing HIF-1α and HIF-2α target genes
Open accessAbstract
Background: Activating KRAS mutations are important for cancer initiation and progression; and have recently been shown to cause primary resistance to therapies targeting the epidermal growth factor receptor. Therefore, strategies are currently in development to overcome treatment resistance due to oncogenic KRAS. The hypoxia-inducible factors-1α and -2α (HIF-1α and HIF-2α) are activated in cancer due to dysregulated ras signaling. Methods: To understand the individual and combined roles of HIF-1α and HIF-2α in cancer metabolism and oncogenic KRAS signaling, we used targeted homologous recombination to disrupt the oncogenic KRAS, HIF-1α, and HIF-2α gene loci in HCT116 colon cancer cells to generate isogenic HCT116 WT KRAS, HCT116 HIF-1α-/-, HCT116 HIF-2α-/-, and HCT116 HIF-1α-/-HIF-2α-/- cell lines. Results: Global gene expression analyses of these cell lines reveal that HIF-1α and HIF-2α work together to modulate cancer metabolism and regulate genes signature overlapping with oncogenic KRAS. Cancer cells with disruption of both HIF-1α and HIF-2α or oncogenic KRAS showed decreased aerobic respiration and ATP production, with increased ROS generation. Conclusion: Our findings suggest novel strategies for treating tumors with oncogenic KRAS mutations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Oncogenic KRAS also upregulates expression of other key glycolytic enzymes, such as PFK1, ENO1, and LDHA28,31–33, thereby promoting glycolytic flux and enabling the production of glycolytic intermediates that can be shunted into other anabolic pathways (Fig 2).”
From The metabolic landscape of RAS-driven cancers from biology to therapy (2021) · cites this paper as [33]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A SIMPLE METHOD FOR THE ISOLATION AND PURIFICATION OF TOTAL LIPIDES FROM ANIMAL TISSUES
Folch, J., Lees, M., & Stanley, G. H. S. (1957) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)64849-5 · Cited by 65,189
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Warburg, O. (1956) · Science · doi:10.1126/science.123.3191.309 · Cited by 13,425
Targeting HIF-1 for cancer therapy
Semenza, G. L. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1187 · Cited by 6,717
Hypoxia — a key regulatory factor in tumour growth
Harris, A. L. (2002) · Nature Reviews Cancer · doi:10.1038/nrc704 · Cited by 5,177
ras oncogenes in human cancer: a review.
Bos, J. L. (1989) · PubMed · Cited by 5,061
Kim, J.-W., Tchernyshyov, I., Semenza, G. L., & Dang, C. V. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.02.002 · Cited by 3,905
HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption
Papandreou, I., Cairns, R. A., Fontana, L., Lim, A. L., & Denko, N. C. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.01.012 · Cited by 2,267
Ohh, M., Park, C. W., Ivan, M., Hoffman, M. A., Kim, T.-Y., Huang, L. E., Pavletich, N., Chau, V., & Kaelin, W. G. (2000) · Nature Cell Biology · doi:10.1038/35017054 · Cited by 1,577
HIF-1 Regulates Cytochrome Oxidase Subunits to Optimize Efficiency of Respiration in Hypoxic Cells
Fukuda, R., Zhang, H., Kim, J.-W., Shimoda, L., Dang, C. V., & Semenza, G. L. (2007) · Cell · doi:10.1016/j.cell.2007.01.047 · Cited by 1,225
Khambata-Ford, S., Garrett, C. R., Meropol, N. J., Basik, M., Harbison, C. T., Wu, S., Wong, T. W., Huang, X., Takimoto, C. H., Godwin, A. K., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.5437 · Cited by 1,125
Ema, M., Taya, S., Yokotani, N., Sogawa, K., Matsuda, Y., & Fujii-Kuriyama, Y. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.9.4273 · Cited by 1,016
Richard, D. E., Berra, E., Gothié, E., Roux, D., & Pouysségur, J. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.46.32631 · Cited by 797
Brahimi-Horn, M. C., Chiche, J., & Pouysségur, J. (2007) · Journal of Molecular Medicine · doi:10.1007/s00109-007-0281-3 · Cited by 765
Kamura, T., Sato, S., Iwaï, K., Czyzyk-Krzeska, M., Conaway, R. C., & Conaway, J. W. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.190332597 · Cited by 652
HIF-1 as a target for drug development
Giaccia, A., Siim, B. G., & Johnson, R. S. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1199 · Cited by 631
Myc Stimulates Nuclearly Encoded Mitochondrial Genes and Mitochondrial Biogenesis
Li, F., Wang, Y., Zeller, K. I., Potter, J. J., Wonsey, D. R., O’Donnell, K. A., Kim, J., Yustein, J. T., Lee, L. A., & Dang, C. V. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.14.6225-6234.2005 · Cited by 615
Hypoxic gene expression and metastasis
Le, Q., Denko, N. C., & Giaccia, A. J. (2004) · Cancer and Metastasis Reviews · doi:10.1023/b:canc.0000031768.89246.d7 · Cited by 467
Defective Remodeling of Cardiolipin and Phosphatidylglycerol in Barth Syndrome
Vreken, P., Valianpour, F., Nijtmans, L. G. J., Grivell, L. A., Plecko, B., Wanders, R. J. A., & Barth, P. G. (2000) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2000.3952 · Cited by 376
Flamme, I., Fröhlich, T., von Reutern, M., Kappel, A., Damert, A., & Risau, W. (1997) · Mechanisms of Development · doi:10.1016/s0925-4773(97)00674-6 · Cited by 373
Sowter, H., Raval, R. R., Moore, J. W., Ratcliffe, P. J., & Harris, A. L. (2003) · PubMed · Cited by 371
Perturbational profiling of a cell-line model of tumorigenesis by using metabolic measurements
Ramanathan, A., Wang, C., & Schreiber, S. L. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0502267102 · Cited by 362
HIF-1 mediates the Warburg effect in clear cell renal carcinoma
Semenza, G. L. (2007) · Journal of Bioenergetics and Biomembranes · doi:10.1007/s10863-007-9081-2 · Cited by 281
Hypoxia, gene expression, and metastasis
Chan, D. A., & Giaccia, A. J. (2007) · Cancer and Metastasis Reviews · doi:10.1007/s10555-007-9063-1 · Cited by 280
Mylonis, I., Chachami, G., Samiotaki, M. K., Panayotou, G., Paraskeva, E., Kalousi, A., Georgatsou, E., Bonanou, S., & Simos, G. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m605058200 · Cited by 266
K-ras as a target for cancer therapy
Friday, B. B., & Adjei, A. A. (2005) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2005.08.001 · Cited by 248
Adaptive landscapes and emergent phenotypes: why do cancers have high glycolysis?
Gillies, R. J., & Gatenby, R. A. (2007) · Journal of Bioenergetics and Biomembranes · doi:10.1007/s10863-007-9085-y · Cited by 219
Aberrant cardiolipin metabolism in the yeast taz1 mutant: a model for Barth syndrome
Gu, Z., Valianpour, F., Chen, S., Vaz, F. M., Hakkaart, G. A. J., Wanders, R. J. A., & Greenberg, M. L. (2003) · Molecular Microbiology · doi:10.1046/j.1365-2958.2003.03802.x · Cited by 199
Bui, T., & Thompson, C. B. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.05.012 · Cited by 197
Agrawal, A., Guttapalli, A. N., Narayan, S., Albert, T. J., Shapiro, I. M., & Risbud, M. V. (2007) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00538.2006 · Cited by 176
Dang, D. T., Chen, F., Gardner, L. B., Cummins, J. M., Rago, C., Bunz, F., Kantsevoy, S. V., & Dang, L. H. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2887 · Cited by 122
Self-citationActivated pp60c-Src Leads to Elevated Hypoxia-inducible Factor (HIF)-1α Expression under Normoxia
Karni, R., Dor, Y., Keshet, E., Meyuhas, O., & Levitzki, A. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m206141200 · Cited by 116
p53-Defective Tumors With a Functional Apoptosome-Mediated Pathway: A New Therapeutic Target
Mashima, T., Oh‐hara, T., Sato, S., Mochizuki, M., Sugimoto, Y., Yamazaki, K., Hamada, J.-I., Tada, M., Moriuchi, T., Ishikawa, Y., et al. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji133 · Cited by 113
de Groof, A. J. C., Lindert, M. T., van Dommelen, M. M. T., Wu, M., Willemse, M. P., Smift, A., Winer, M., Oerlemans, F. T. J. J., Pluk, H., Fransen, J. A. M., et al. (2009) · Molecular Cancer · doi:10.1186/1476-4598-8-54 · Cited by 80
Determinants of RASistance to Anti–Epidermal Growth Factor Receptor Agents
Baselga, J. M., & Rosen, N. X. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.3700 · Cited by 76
The oncoprotein H-RasV12 increases mitochondrial metabolism
Telang, S., Lane, A. N., Nelson, K. K., Arumugam, S., & Chesney, J. A. (2007) · Molecular Cancer · doi:10.1186/1476-4598-6-77 · Cited by 71
Cooke, D., & O’Kennedy, R. J. (1999) · Analytical Biochemistry · doi:10.1006/abio.1999.4274 · Cited by 43
ras Oncogenes and the molecular mechanisms of carcinogenesis
Weinberg, R. A. (1984) · Blood · doi:10.1182/blood.v64.6.1143.bloodjournal6461143 · Cited by 41
ras Oncogenes and the molecular mechanisms of carcinogenesis
Weinberg, R. A. (1984) · Blood · doi:10.1182/blood.v64.6.1143.1143 · Cited by 34
CDX2 promotes anchorage-independent growth by transcriptional repression of IGFBP-3
Chun, S. Y., Chen, F., Washburn, J. G., MacDonald, J. W., Innes, K. L., Zhao, R., Cruz-Correa, M. R., Dang, L. H., & Dang, D. T. (2007) · Oncogene · doi:10.1038/sj.onc.1210258 · Cited by 22
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Deconvoluting the context-dependent role for autophagy in cancer
White, E. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3262 · Cited by 1,758
Kamphorst, J. J., Cross, J. R., Fan, J., de Stanchina, E., Mathew, R., White, E. P., Thompson, C. B., & Rabinowitz, J. D. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1307237110 · Cited by 726
Fan, J., Kamphorst, J. J., Mathew, R., Chung, M. K., White, E., Shlomi, T., & Rabinowitz, J. D. (2013) · Molecular Systems Biology · doi:10.1038/msb.2013.65 · Cited by 428
The metabolic landscape of RAS-driven cancers from biology to therapy
Mukhopadhyay, S., Vander Heiden, M. G., & McCormick, F. (2021) · Nature Cancer · doi:10.1038/s43018-021-00184-x · Cited by 315
Vincent, E. E., Sergushichev, A., Griss, T., Gingras, M., Samborska, B., Ntimbane, T., Coelho, P. P., Blagih, J., Raissi, T. C., Choinière, L., et al. (2015) · Molecular Cell · doi:10.1016/j.molcel.2015.08.013 · Cited by 281
Metadata
- Authors
- Chun, S. Y., Johnson, C., Washburn, J. G., Cruz-Correa, M. R., Dang, D. T., & Dang, L. H.
- Affiliations
- University of Michigan (US)
- University of Puerto Rico System (PR)
- University of Florida (US)
- Corresponding author
- Dang, Long H
- Venue
- Molecular Cancer
- Published
- 2010-11-13
- Volume
- 9
- Issue
- 1
- Pages
- 293-293
- ISSN
- 1476-4598 (ISSN-L)
- PMC
- PMC2999617
- OpenAlex
- W2107951449
- Cited by
- 109
- References
- 39
- Citations by year
- 2026: 2 · 2025: 6 · 2024: 8 · 2023: 6 · 2022: 14 · 2021: 12 · 2020: 8 · 2019: 4 · 2018: 3 · 2017: 3 · 2016: 6 · 2015: 4 · 2014: 13 · 2013: 8 · 2012: 3
- FWCI
- 2.01
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- Locations
- Molecular Cancer (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Deep Blue (University of Michigan) (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Pfizer
- National Comprehensive Cancer Network
- National Institutes of Health
- University of Michigan Comprehensive Cancer Center
- National Cancer Institute (R21CA115809, K22CA111897)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Kruppel-like factors research
- Keywords
- oncogenic KRAS, HIF-1α, HIF-2α, hypoxia-inducible factor, colon cancer, mitochondrial metabolism, aerobic respiration, reactive oxygen species, ATP production, KRAS mutation, isogenic cell lines, HCT116 cells, cancer metabolism
- MeSH terms
- Endothelial PAS Domain-Containing Protein 1, Adenosine Triphosphate, Colonic Neoplasms, Humans, Mitochondria, Oxygen Consumption, Proto-Oncogene Proteins, Blotting, Western, Proto-Oncogene Proteins p21(ras), Mutagenesis, Site-Directed, Reactive Oxygen Species, ras Proteins, Reverse Transcriptase Polymerase Chain Reaction, Gene Expression Profiling, HCT116 Cells, Cell Line, Tumor, Basic Helix-Loop-Helix Proteins, Hypoxia-Inducible Factor 1, alpha Subunit
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
